GleamWall
中文EN

BFRG BullFrog AI Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829247 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY4.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-184.0%
ROA-152.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.75x
Interest coverage-1,202.80x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$116,670—
Cost of revenue$94,778—
Gross profit$21,892—
R&D expense$1.80M$2.22M
SG&A expense$4.82M$5.01M
Operating income-$6.59M-$7.24M
Interest expense$5,629$18,158
Net income-$6.50M-$6.99M
EBITDA-$6.59M-$7.23M
EPS (basic)-0.63-0.85
EPS (diluted)-0.63-0.85
Weighted avg. shares (diluted)10.34M8.25M
Balance sheet
Cash & equivalents$2.18M$5.44M
Receivables$0—
Current assets$2.58M$5.55M
PP&E, net$2,525$4,250
Total assets$2.81M$5.55M
Current liabilities$672,022$588,090
Total liabilities$672,022$588,090
Shareholders' equity$2.14M$4.96M
Shares outstanding11.42M9.11M
Cash flow statement
Operating cash flow-$5.52M-$5.61M
Financing cash flow$2.37M$8.42M
Depreciation & amortization$1,725$1,724
Stock-based compensation$1.01M$943,649

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.